Physician profile
Bethany Buchanan
NPI 1477517969
$3,873.09
in general payments reported to CMS, 2019-2025
21 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $804 · 2022: $947 · 2023: $946 · 2024: $836 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $973.53 | 2021-2025 | |
| Novo Nordisk INC | $847.36 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $436.44 | 2021-2025 | Farxiga, Airsupra |
| Antares Pharma, INC. | $431.02 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $248.74 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $199.73 | 2022 | |
| Astellas Pharma US INC | $113.64 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.00 | 2023 | |
| Axsome Therapeutics, INC. | $92.21 | 2023 | Auvelity |
| Pfizer INC. | $59.77 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $58.88 | 2022-2023 | Aveed |
| Biohaven Pharmaceuticals, INC. | $56.49 | 2021 | |
| Qol Medical, LLC | $46.22 | 2023-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $37.33 | 2021-2022 | |
| Amarin Pharma, INC. | $30.77 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.38 | 2024 | Injectafer |
| Gilead Sciences, INC. | $25.83 | 2024 | |
| Pharmacosmos Therapeutics INC. | $23.62 | 2023 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $22.74 | 2023 | |
| Halozyme INC | $20.90 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.